| Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
| Name: |
emocha Mobile Health, Inc |
| Street 1: |
1812 Ashland Ave |
| Street 2: |
1st Fl, Ste B |
| City: |
Baltimore |
| Province: |
|
| Post Code: |
21205 |
| Country: |
United States of America |
| Phone: |
9149601080 |
| Organization Email: |
info@emocha.com |
| Web Site: |
http://www.emocha.com/ |
| Other Online Presence: |
|
Focal Point Contact Information |
| Salutation: |
Mr |
| First Name: |
Morad |
| Last Name: |
Elmi |
| Title: |
Managing Director |
| Email: |
melmi@emocha.com |
| Phone: |
|
|
Alternate Focal Point Contact Information |
| Salutation: |
Ms |
| First Name: |
Michelle |
| Last Name: |
Mendes |
| Title: |
Director, Marketing & Communications |
| Email: |
mmendes@emocha.com |
| Phone: |
|
|
General Information |
| Board Constituency: |
Private sector |
| Is your organization legally registered in your country: |
Yes |
| If yes, please enter your registration number: |
|
| Organization Type - Primary: |
Private Sector |
| Organization Type - Secondary: |
None |
| Organization Description: |
| emocha Mobile Health is a mobile health company for public health. emocha build's mobile and web applications that link patients to care and ensure high medication adherence. Their flagship application, miDOT, provides tools for video-based directly observed therapy (VDOT), and empowers healthcare providers with advanced analytics for their patient population. emocha works with TB thought leaders and public health departments around the U.S. to build advanced mobile technology that empowers patients to adhere to their TB therapy. |
| |
| Do you know about the UNHLM declaration: |
|
Specializations / Areas of Work |
Technical Assistance
|
Other Organization Information |
| Total number of staff in your organization: |
6 - 10 |
| Number of full-time staff who are directly involved with TB: |
1 - 5 |
| Number of part-time staff who are directly involved with TB: |
0 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| How did you hear about the Stop TB Partnership: |
Media |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
| Why do you wish join the Stop TB Partnership: |
Network with other partners |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| emocha works closely with the public health departments that use miDOT for video-based DOT. Through advancements of our technology and constant user feedback from health departments that shape our country's national TB plan, emocha better serves the patients and providers using miDOT. With SBIR grant funding through the NIH, we have built a comprehensive case management portal, and contributed to the research pool with peer-reviewed data on asynchronous, video-based DOT strategies. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
United States of America |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
India
South Africa
United States of America
|
Contribution |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
TB Care Delivery:
emocha's application for video-based directly observed therapy (VDOT) allows for efficient, cost-effective delivery of DOT around the United States. Advanced patient analytics allow providers to track their patient population, while providing the highest level of patient autonomy as patients complete TB therapy. Adherence rates have been comparable to in-person DOT, making miDOT a sought-after solution for remote patient management in the TB space. In March 2015, a team of US and South African TB experts along with the technology experts at emocha developed a platform that has revolutionized the linkage to care for multi-drug resistant tuberculosis (MDR-TB) patients (miLINC). The miLINC platform consists of three synchronized applications that guide patients from primary health clinics to treatment initiation at specialized MDR-TB clinics.
Research:
emocha’s application miDOT (mobile internet Directly Observed Therapy) won an SBIR award from the NIH in November 2015. The study focused on Tuberculosis (TB) patients at four public health departments across Maryland, which gathered data on usability, patient adherence, and cost savings of the asynchronous smartphone and web application. The data will be used to improve the miDOT system and expand opportunities to implement video-based DOT as a tool for eliminating TB. Preliminary data will be released in 2017, and a proposal has been submitted to continue Phase II of this study with more sites around the United States.
|
Declaration |
Declaration of interests:
No conflicts of interest were delacred.
|
| Application date: |
February 20, 2017 |
| Last updated: |
September 2, 2018 |
|
